Researchers found that an investigational drug called nalbuphine extended-release (ER) may significantly reduce chronic cough in people with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). In a recent Phase 2b trial, participants who took nalbuphine ER experienced a notable decrease in cough frequency compared to those on a placebo. This is particularly important for the estimated 140,000 people in the U.S. suffering from IPF, of whom about two-thirds deal with uncontrolled chronic cough, impacting their quality of life.

The findings from the trial suggest that nalbuphine ER could help improve daily living for those affected by chronic cough associated with serious lung diseases. The study involved 165 patients who were given varying doses of the drug over six weeks, and the results showed a clear reduction in cough bouts. This could mean less discomfort and better overall health for individuals struggling with persistent coughs, which can lead to more severe health issues and hospitalizations.

While the results are promising, it’s important to note that this research is still in the early stages. The Phase 2b CORAL trial is a randomized, placebo-controlled study, which provides a good level of evidence, but further research is needed to confirm these benefits in larger populations and over longer periods. The drug has not yet received FDA approval, and its safety and efficacy are still under evaluation.

If you or someone you know suffers from chronic cough, it may be worth discussing these developments with a healthcare provider, especially as new treatments like nalbuphine ER are being studied. Staying informed about emerging therapies could lead to better management of chronic cough and improved quality of life.

Source: globenewswire.com